Saturday Morning Coffee with Experts in NASH: What Is The Update?
Premiere Date: Tuesday, November 10, 2020This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, November 10, 2021
Note: Credit Is No Longer Available
 | Mazen Noureddin, MD, MHSc Director, Fatty Liver Program Karsh Division of Gastroenterology and Hepatology Comprehensive Transplant Center Cedars-Sinai Medical Center Los Angeles, CA |
 | Rohit Loomba, MD, MHSc Director, NAFLD Research Center Professor of Medicine Director of Hepatology and Vice Chief Division of Gastroenterology Adjunct Professor, Division of Epidemiology University of California at San Diego San Diego, CA |
 | Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD, President, Inova Medicine Services Chairman, Clinical Research, Inova Health System Professor and Chairman of Department of Medicine Inova Fairfax Medical Campus Falls Church, VA |
Non-alcoholic steatohepatitis (NASH) is a severe and potentially life-threatening form of non-alcoholic fatty liver disease (NAFLD) that has emerged as a major health and societal burden in the United States. Of the estimated one in four individuals who have NAFLD, one in five has NASH, and although the pathogenesis of NAFLD and NASH have not been fully elucidated, it is a result of several pathways that may lead to advanced fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and death.
This CME Outfitters enduring material features a renowned panel of experts highlighting the underlying mechanisms of NASH via innovative augmented reality (AR) animations and presenting real-world case scenarios to share clinical insights on how to choose appropriate non-invasive diagnostic modalities, as well as translate latest data on emerging targeted therapies and their implications for clinical practice.
At the end of this CE activity, participants should be able to:
- Summarize the epidemiology of NAFLD and NASH and the factors driving the progression to advanced fibrosis.
- Determine candidates for liver biopsy versus noninvasive modalities for the staging of fibrosis in NASH.
- Evaluate the clinical significance of the latest clinical data on emerging targeted therapies for NASH.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize the epidemiology of NAFLD and NASH and the factors driving the progression to advanced fibrosis.
- Identify candidates for liver biopsy versus noninvasive modalities for the staging of fibrosis in NASH.
- Evaluate the clinical significance of the latest clinical data on emerging targeted therapies for NASH.
Supported by an educational grant from Intercept Pharmaceuticals, Inc.
Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number:
Enduring: 0376-0000-20-150-H01-P
Type: knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Noureddin reports that he receives research support from Allergan; Bristol-Myers Squibb Company; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Galectin Therapeutics Inc.; Galmed Pharmaceuticals; GENFIT; Gilead Sciences, Inc.; Novartis; Shire; and Zydus Pharmaceuticals, Inc. He is on the advisory board or speakers bureau for Abbott; Allergan; Blade Therapeutics; EchosensTM North America; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novartis; OWL; Pfizer Inc.; Roche Diagnostics, North America; and Siemens. He is a stock shareholder (directly purchased) of Ananetos; and Viking Therapeutics, Inc.
Dr. Loomba reports that his institution has received grant support from Allergan; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Cirius Therapeutics; Eli Lilly and Company; Galectin Therapeutics Inc.; Galmed Pharmaceuticals Ltd.; GE Healthcare Life Sciences; Genfit; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; GRAIL, Inc.; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Merck & Co., Inc.; NGM Biopharmaceuticals; NuSirt Biopharma; Pfizer Inc.; pH Pharma Co., Ltd.; Prometheus Laboratories Inc.; and Siemens. He is a consultant or advisory board member for Alnylam Pharmaceuticals,Inc./Regeneron Pharmaceuticals Inc.; Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Bird Rock Bio; Boehringer Inghelheim; Bristol-Myer Squibb Company; Celgene Corporation; Cirius Therapeutics; CohBar, Inc.; Conatus Pharmaceuticals Inc.; Eli Lilly and Company; Galmed Pharmaceuticals Ltd.; Gemphire Therapeutics Inc.; Gilead Sciences, Inc.; Glimpse Bio; GNI Group Ltd.; GRI Bio; Inipharm, Inc.; Intercept Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Metacrine, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Prometheus Laboratories Inc.; Promethera? Biosciences; Sanofi-Aventis U.S. LLC; Siemens; and Viking Therapeutics, Inc. He receives other financial or material support as the co-founder of Liponexus, Inc.
Dr. Younossi reports that he receives research support from Bristol-Myers Squibb Company; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.; Merck & Co., Inc.; and Siemens. He is a consultant for Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Siemens; and Terns Pharmaceuticals, Inc.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-104-111020-60
